Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
Pharmacotherapy. 2015 May; 35(5):536-45.P

Abstract

Leishmaniasis is a protozoan infection native to various countries, including those in South America and Southeast Asia. Although the incidence of leishmaniasis is low in the United States, it is an important cause of infection in individuals traveling to endemic areas. Various treatment modalities are available, depending on their availability in the geographic region. In the United States, the treatment of choice is considered to be liposomal amphotericin, although other therapies have been explored. In 2014, miltefosine became the first orally available medication approved for the treatment of leishmaniasis in the United States. Based on available data, miltefosine is a first-line option for the treatment of leishmaniasis. Miltefosine is equally efficacious to and may be as tolerable as liposomal amphotericin B. The most common adverse effects of miltefosine are vomiting, diarrhea, and transient liver enzyme level elevation. Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year. In the meantime, the drug may be obtained through the Centers for Disease Control and Prevention expanded-access investigational new drug protocol.

Authors+Show Affiliations

Department of Pharmacy, Cedars-Sinai Medical Center, Los Angeles, California.Department of Pharmacy, Cedars-Sinai Medical Center, Los Angeles, California.Department of Pharmacy, Alexian Brothers Health System, Elk Grove Village, Illinois.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25940658

Citation

Vakil, Niyati H., et al. "Pharmacotherapy for Leishmaniasis in the United States: Focus On Miltefosine." Pharmacotherapy, vol. 35, no. 5, 2015, pp. 536-45.
Vakil NH, Fujinami N, Shah PJ. Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. Pharmacotherapy. 2015;35(5):536-45.
Vakil, N. H., Fujinami, N., & Shah, P. J. (2015). Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. Pharmacotherapy, 35(5), 536-45. https://doi.org/10.1002/phar.1585
Vakil NH, Fujinami N, Shah PJ. Pharmacotherapy for Leishmaniasis in the United States: Focus On Miltefosine. Pharmacotherapy. 2015;35(5):536-45. PubMed PMID: 25940658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. AU - Vakil,Niyati H, AU - Fujinami,Noriko, AU - Shah,Punit J, Y1 - 2015/05/04/ PY - 2015/5/6/entrez PY - 2015/5/6/pubmed PY - 2015/12/22/medline KW - cutaneous leishmaniasis KW - leishmaniasis KW - mitefosine KW - mucosal leishmaniasis KW - visceral leishmaniasis SP - 536 EP - 45 JF - Pharmacotherapy JO - Pharmacotherapy VL - 35 IS - 5 N2 - Leishmaniasis is a protozoan infection native to various countries, including those in South America and Southeast Asia. Although the incidence of leishmaniasis is low in the United States, it is an important cause of infection in individuals traveling to endemic areas. Various treatment modalities are available, depending on their availability in the geographic region. In the United States, the treatment of choice is considered to be liposomal amphotericin, although other therapies have been explored. In 2014, miltefosine became the first orally available medication approved for the treatment of leishmaniasis in the United States. Based on available data, miltefosine is a first-line option for the treatment of leishmaniasis. Miltefosine is equally efficacious to and may be as tolerable as liposomal amphotericin B. The most common adverse effects of miltefosine are vomiting, diarrhea, and transient liver enzyme level elevation. Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year. In the meantime, the drug may be obtained through the Centers for Disease Control and Prevention expanded-access investigational new drug protocol. SN - 1875-9114 UR - https://www.unboundmedicine.com/medline/citation/25940658/Pharmacotherapy_for_leishmaniasis_in_the_United_States:_focus_on_miltefosine_ L2 - https://doi.org/10.1002/phar.1585 DB - PRIME DP - Unbound Medicine ER -